# Hinge Bio

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/hinge-bio

- Industry: Biotechnology
- Headquarters: Burlingame, US
- Website: www.hingebio.com
- Total disclosed funding: $31M
- Latest round: Series A (Dec 31, 2024)
- Investors on record: 3

## About

Based in California, US, Hinge Bio, Inc. operates as a biotechnology company that develops therapeutics for autoimmunity, cancer, inflammatory diseases, and infectious diseases. In January 2025, Hinge Bio, Inc. raised USD 30 million in series A funding led by investor Point72, with participation from other investors InVivium Capital and Lightswitch Capital.

The company specializes in developing therapeutics utilizing its proprietary GEM-DIMER™ platform, which addresses challenges in the treatment of autoimmunity, cancer, inflammatory diseases, and infectious diseases. The GEM-DIMER™ technology enables cooperative binding to disease targets, resulting in enhanced therapeutic efficacy and safety compared to conventional methods. This innovation allows for greater multivalency and multispecificity, producing biologic molecules with novel functionalities. Hinge Bio's products aim to tackle issues such as resistance and inadequate efficacy, catering primarily to healthcare institutions, research organizations, and pharmaceutical companies engaged in advanced therapeutic development in North America, Europe, and select markets in Asia.

## Funding rounds

- Series A, Dec 31, 2024, $31M — Point72 Asset Management, Lightswitch Capital, InVivium Capital

## Investors

- Point72 Asset Management — Series A
- Lightswitch Capital (https://capitalatlas.ai/funds/lightswitch-capital) — Series A
- InVivium Capital (https://capitalatlas.ai/funds/invivium-capital) — Series A